On July 13, 2018, the United States Food and Drug Administration (FDA) sent out alerts to health care professionals and patients regarding a voluntary recall of medications containing valsartan, after an impurity was found. The impurity is an organic chemical known as nitrosodimethylamine (“NDMA”). NDMA is classified as a probable human carcinogen. According to the … Read More
Valsartan Impurity, Probable Cause of Cancer
